All these features make HSPB1 an attractive therapeutic target, and indeed HSPB1 inhibitors have been revealed to be clinically effective in inhibiting tumour progression, promoting apoptosis and sensitizing cancer cells to other chemotherapies in pancreatic cancer, head and neck squamous cell carcinoma and prostate cancer [37–40]. The gene discussed is HSPB1; the disease is pancreatic neoplasm.